tuberculosis

AU1235 is a Mycobacterium tuberculosis inhibitor.

(S)-5-chloro-N-(1-((4-chlorophenyl)amino)-1-oxo-3-phenylpropan-2-yl)-2-hydroxybenzamide has antifungal and tuberculostatic activities.

Cloxiquine (Dermofongin) is a monohalogenated 8-hydroxyquinoline with activity against bacteria, fungi, and protozoa.

Kanamycin sulfate (Kanamycin monosulfate) is an aminoglycoside antibiotic that interferes with protein synthesis by binding to the 70S ribosomal subunit of bacteria. Kanamycin sulfate exhibits antimicrobial activity against both Gram-positive and Gram-negative bacteria, as well as mycoplasmas.

Imidazoleacetic acid hydrochloride (I4AA) is an imidazole derivative with potential antituberculosis properties. It also used in the preparation of acyl guanidine inhibitors of β-secretase.

Rifamycin S is a potent DNA-dependent RNA polymerase inhibitor,is a quinone and an antibiotic agnet against Gram-positive bacteria

1-Hydroxy-2-butanone, a natural product extractable from bamboo juice and tomato leaves, exhibits anti-tuberculosis activity.

TBA-7371 (DprE1-IN-1) is a potent inhibitor of DprE1 and PDE6.

Q203 (Telacebec) is a novel potent anti-tuberculosis agent targeting cytochrome b subunit qcrB and inhibits M. tuberculosis H37Rv (MIC50: 2.7 nM).

NITD-916 is an orally active and highly lipophilic inhibitor of Mycobacterium enoyl reductase InhA with an IC50 of 570 nM.NITD-916 is a potent 4-hydroxy-2-pyridone derivative that forms a ternary complex with InhA and NADH, preventing access to the fatty acyl substrate-binding pocket.NITD-916 exhibits antituberculosis activity.

Tuberculosis inhibitor 1 is a potent, non-cytotoxic inhibitor of Trypanosoma brucei growth [EC50: 5 nM].

Mycobacterium Tuberculosis-IN-6 (compound b1) is an inhibitor of the enoyl reductase InhA from Mycobacterium tuberculosis, with an IC50 value of 7.74 μM. It is useful in antibacterial research.

Mycobacterium Tuberculosis-IN-7 (Compound 4c) inhibits M. tuberculosis H37Ra with an MIC of 5.34 μg/mL and exhibits mild cytotoxicity against cancer cells Vero, A549, and HepG2 (IC50 > 50 μM).

Mycobacterium Tuberculosis-IN-8 (Compound 6g) is a selective inhibitor of Mycobacterium tuberculosis (MTB), with a MIC value of 6.25 µg/mL against MTB H37Rv. It demonstrates potent antitubercular activity by inhibiting mycolic acid biosynthesis, which is crucial for maintaining bacterial cell wall integrity. Mycobacterium Tuberculosis-IN-8 holds potential for research in antitubercular agents.

Tuberculosis inhibitor 3 (compound 2i) is a highly potent and orally bioavailable anti-tuberculosis drug with in vitro antidrug activity of MIC < 0.016 μg mL against both drug-sensitive and drug-resistant Mycobacterium tuberculosis, H37RV & MDR-TB.

Tuberculosis inhibitor 5 (Compound 11i) is a potent antimycobacterial biphenyl analogue and anti-tuberculosis agent with no apparent cytotoxicity.

Tuberculosis inhibitor 4 (compound 16) is a spirothiazolidinone derived from mandelic acid, exhibiting potent antimycobacterial activity by inhibiting 98% of Mycobacterium tuberculosis strain H37Rv at concentrations below 6 μg mL.

Tuberculosis inhibitor 6 (compound 2c), a 3-methoxy-2-phenylimidazo[1,2-b]pyridazine derivative, is highly active against Mycobacterium tuberculosis (MIC 90 of ≤1.66 μM) and Mycobacterium marinum (MIC 90 of 2.65 μM) [1].

Tuberculosis inhibitor 7 (compound 2d), a 3-methoxy-2-phenylimidazo[1,2-b]pyridazine derivative, exhibits potent activity against Mycobacterium tuberculosis and Mycobacterium marinum, with both displaying a MIC 90 of 0.63 μM [1].

Tuberculosis inhibitor 8 (compound 3b), a 3-methoxy-2-phenylimidazo[1,2-b]pyridazine derivative, exhibits potent activity against both Mycobacterium tuberculosis and Mycobacterium marinum with an MIC 90 of 0.69 μM [1].

Tuberculosis inhibitor 9 (compound 3d), a 3-methoxy-2-phenylimidazo[1,2-b]pyridazine derivative, exhibits potent activity against Mycobacterium tuberculosis and Mycobacterium marinum, with an MIC 90 of 0.64 μM for both organisms [1].

Tuberculosis Inhibitor 12, an oxadiazole derivative, effectively inhibits Mycobacterium tuberculosis, demonstrating inhibition rates of 82% and 78% at a concentration of 20 μM on 7H9-Tw-OADC media, respectively [1].

Compound 14, also known as Tuberculosis Inhibitor 11, enhances the antimycobacterial efficacy of antitubercular agent [1].

Tuberculosis Inhibitor 10 moderately inhibits the enzyme MSMEG_6649 and potentiates the antimycobacterial activity of PAS [1].